Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Gamme d'année
1.
Int. braz. j. urol ; 42(1): 139-145, Jan.-Feb. 2016. graf
Article Dans Anglais | LILACS | ID: lil-777321

Résumé

ABSTRACT Purpose To investigate whether intracavernosal injection of short hairpin RNA for IGFBP-3 could improve erectile function in streptozotocin-induced diabetic rats. Materials and methods After 12 weeks of IGFBP-3 short hairpin RNA injection treatment, intracavernous pressure responses to electrical stimulation of cavernous nerves were evaluated. The expression of IGFBP-3 and IGF-1 at mRNA and protein levels were detected by quantitative real-time PCR analysis and Western blot, respectively. The concentration of cavernous cyclic guanosine monophosphate was detected by enzyme-linked immunosorbent assay. Results At 12 weeks after intracavernous administration of IGFBP-3 shRNA, the cavernosal pressure was significantly increased in response to the cavernous nerves stimulation compared to the diabetic group (P<0.05). Cavernous IGFBP-3 expression at both mRNA and protein levels was significantly inhibited. At the same time, cavernous IGF-1 expression was significantly increased in the IGFBP-3 shRNA treatment group compared to the diabetic group (P<0.01). Cavernous cyclic guanosine monophosphate concentration was significantly increased in the IGFBP-3 shRNA treatment group compared to the diabetic group (P<0.01). Conclusions Gene transfer of IGFBP-3 shRNA could improve erectile function via the restoration of cavernous IGF-1 bioavailability and an increase of cavernous cGMP concentration in the pathogenesis of erectile dysfunction in streptozotocin-induced diabetic rats.


Sujets)
Animaux , Mâle , Pénis/effets des médicaments et des substances chimiques , Protéine-3 de liaison aux IGF/pharmacocinétique , Petit ARN interférent/pharmacocinétique , Diabète expérimental/physiopathologie , Dysfonctionnement érectile/physiopathologie , Dysfonctionnement érectile/traitement médicamenteux , Facteur de croissance IGF-I/analyse , Facteur de croissance IGF-I/effets des médicaments et des substances chimiques , Test ELISA , Biodisponibilité , Répartition aléatoire , Technique de Western , Reproductibilité des résultats , Rat Wistar , Streptozocine , Diabète expérimental/complications , Réaction de polymérisation en chaine en temps réel , Dysfonctionnement érectile/étiologie , Injections
SÉLECTION CITATIONS
Détails de la recherche